GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » Price-to-Owner-Earnings

INZY (Inozyme Pharma) Price-to-Owner-Earnings : (As of Mar. 30, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma Price-to-Owner-Earnings?

As of today (2025-03-30), Inozyme Pharma's share price is $0.9202. Inozyme Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Inozyme Pharma's Price-to-Owner-Earnings or its related term are showing as below:


INZY's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.73
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-03-30), Inozyme Pharma's share price is $0.9202. Inozyme Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.63. Therefore, Inozyme Pharma's PE Ratio (TTM) for today is At Loss.

As of today (2025-03-30), Inozyme Pharma's share price is $0.9202. Inozyme Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.63. Therefore, Inozyme Pharma's PE Ratio without NRI for today is At Loss.


Inozyme Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Inozyme Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma Price-to-Owner-Earnings Chart

Inozyme Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Inozyme Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inozyme Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Inozyme Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inozyme Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Inozyme Pharma's Price-to-Owner-Earnings falls into.


;
;

Inozyme Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Inozyme Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.9202/-1.51
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inozyme Pharma  (NAS:INZY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Inozyme Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Inozyme Pharma Business Description

Traded in Other Exchanges
N/A
Address
321 Summer Street, Suite 400, Boston, MA, USA, 02210
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
Executives
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Robert Lorne Hopfner director, 10 percent owner C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p. director 501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton officer: COO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian officer: SVP, CFO 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke officer: See Remarks ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte director, 10 percent owner, officer: See Remarks PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc. director 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma officer: Interim CFO C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert officer: SVP, CMO C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell 10 percent owner